Aldose reductase inhibitors for the treatment of diabetic polyneuropathy

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Chalk, Colin ^a   Benstead, T J ^b   Moore, F ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Aldehyde reductase *antagonists inhibitors ; Diabetic neuropathies *drug therapy ; Enzyme inhibitors *therapeutic use ; Peripheral nervous system diseases drug therapy ; Polyneuropathies *drug therapy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; PLACEBO; PONALRESTAT; RANIRESTAT; SORBINIL; TOLRESTAT; ZENARESTAT; ZOPOLRESTAT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FOOT ULCER; HUMAN; LIVER FUNCTION; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SENSORY ANALYSIS; SIDE EFFECT;

EID: 44949089602     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004572.pub2     Document Type: Review

References (63)

1. Baba 2006 {published data only} Baba M, Kimura K-I, Suda T, Yagihashi S. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. Journal of the Peripheral Nervous System 2006;11(2):176-8. [MEDLINE: 62].
2. Boulton 1989 {published data only} Boulton AJM, Atiea J, de Leeuw IH, Lemkes H, MacLeod AF, MacRury S, et al North European Tolrestat Study Group. The efficacy and safety of the aldose-reductase inhibitor tolrestat in the treatment of chronic sensorimotor diabetic neuropathy. Diabetologia 1989;32:469A. [MEDLINE: 13].
3. Boulton 1990 {published data only} Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33(7):431-7. [MEDLINE: 14].
4. Brown 2004 {published data only} Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, et al.Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 2004;27(5):1153-9. [MEDLINE: 35].
5. Christensen 1987 {published data only} Christensen JE, Larsen AB, Gregersen G. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]. [Danish] [Diabetisk neuropati: Behandlingsforsog med en aldosereduktasehaemmer (Sorbinil)]. Ugeskrift for Laeger 1987;149(46):3111-4. [MEDLINE: 19].
6. Daniele 1995 {published data only} Daniele E, Coco MP. The therapy of diabetic peripheral neuropathy with tolrestat: Is this drug really useful? [Italian] [La terapia della neuropatia diabetica periferica con tolrestat: tale farmaco e realmente utile?]. Clinica Terapeutica 1995;146(12):793-9. [MEDLINE: 25].
7. Dietrich 1990 {published data only} Dietrich E, Stracke H, Federlin K. The effects of the aldose reductase inhibitor 'Statil' on diabetic peripheral neuropathy. Diabetologia 1990;33:A167. [MEDLINE: 28].
8. Fabiani 1995 {published data only} Fabiani F, De Vincentis N, Staffilano A. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Diabete et Metabolisme 1995;21(5):360-4. [MEDLINE: 30].
9. Faes 1993 {published data only} Faes TJ, Yff GA, DeWeerdt O, Lanting P, Heimans JJ, Bertelsmann FW. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. Journal of Neurology 1993;240(3):156-60. [MEDLINE: 31].
10. Fagius 1985 {published data only} Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: A 24-week controlled trial. Diabetologia 1985;28(6):323-9. [MEDLINE: 32].
11. Florkowski 1990 * {published data only} Florkowski CM, Rowe BR, Nightingale S, Barnett AH. A six-month randomized placebo-controlled trial of the aldose reductase inhibitor ponalrestat in chronic symptomatic peripheral neuropathy. International Diabetes Federation Symposium on Diabetic Neuropathy , Sydney, Australia. Chichester: John Wiley and Sons, 1990:143-8.
12. Florkowski 1991 {published data only} Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991;40(1):129-133. [MEDLINE: 37].
13. Giugliano 1993 {published data only} Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R. Tolrestat for mild diabetic neuropathy: A 52-week, randomized, placebo- controlled trial. Annals of Internal Medicine 1993;118(1):7-11. [MEDLINE: 44].
14. Giugliano 1995 {published data only} Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L, et al.Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995;18(4):536- 41. [MEDLINE: 42].
15. Greene 1999 {published data only} Greene DA, Arezzo JC, Brown MB, Zenarestat Study Group. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy [erratum appears in Neurology 2001;56(8):1124]. Neurology 1999;53(3):580-91. [MEDLINE: 49].
16. Guy 1988 {published data only} Guy RJ, Gilbey SG, Sheehy M, Asselman P, Watkins PJ. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 1988;31(4):214-20. [MEDLINE: 53].
17. Hotta 2001 {published data only} Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al The SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24(10):1776-82. [MEDLINE: 299].
18. Hotta 2006 {published data only} Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al The ADCT Study Group. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic periheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 2006;29(7):1538-44.
19. Jennings 1990 {published data only} Jennings PE, Nightingale S, Le Guen C, Lawson N, Williamson JR, Hoffman P, et al.Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy. Diabetic Medicine 1990;7(1):63-8. [MEDLINE: 332].
20. Jespersen 1986 {published data only} Jespersen J, Gram J, Christensen JE. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study. Haemostasis 1986;16(6):453-7. [MEDLINE: 336].
21. Johnson 2004 {published data only} Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 2004;27(2):448-54. [MEDLINE: 38].
22. Krentz 1992 {published data only} Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabetic Medicine 1992;9(5):463-8. [MEDLINE: 376].
23. Macleod 1992 {published data only} Macleod AF, Boulton AJ, Owens DR, Van Rooy P, van Gerven JM, MacRury S, et al North European Tolrestat Study Group. A multicentre trial of the aldose-reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy. Diabetes & Metabolism 1992;18(1):14-20. [MEDLINE: 405].
24. Martyn 1987 {published data only} Martyn CN, Reid W, Young RJ, Ewing DJ, Clarke BF. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Diabetes 1987;36(9):987-90. [MEDLINE: 417].
25. Nakayama 2001 {published data only} Nakayama M. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 2001;24(6):1093-1098. [MEDLINE: 438].
26. O'Hare 1988 {published data only} O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IA, Corrall RJ. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabetic Medicine 1988;5(6):537-42. [MEDLINE: 453].
27. Salmon 1991 {published data only} Salmon P, Perkins CM, Tomkin GH. Diabetic neuropathy and aldose reductase inhibition. Diabetes, Nutrition & Metabolism - Clinical & Experimental 1991;4(2):135-39. [MEDLINE: 516].
28. Sima 1988 {published data only} Sima AAF, Bril V, Nathaniel V, McEwen TAJ, Brown MB, Lattimer SA, et al.Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. New England Journal of Medicine 1988;319(9):548-55. [MEDLINE: 557].
29. SRG 1993 {published data only} Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993;43(6):1141-9. [MEDLINE: 6].
30. Stracke 1994 {published data only} Stracke H, Dietrich E. Influence of Ponalrestat, an aldose-reductase inhibitor, on diabetic polyneuropathy. [German] [Der Einfluss des Aldose-Reduktase-Inhibitors Ponalrestat auf die diabetische Polyneuropathie]. Medizinische Welt 1994;45(3):84-89. [MEDLINE: 560].
31. Sundkvist 1992 {published data only} Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, et al.Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. Journal of Diabetes and its Complications 1992;6(2):123-30. [MEDLINE: 561].
32. van Gerven 1992 {published data only} van Gerven JM, Lemkes HH, van Dijk JG. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. Journal of Diabetes and its Complications 1992;6(1):45-8. [MEDLINE: 566].
33. van Gerven 1993 * {published data only} van Gerven JM. Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy. Diabetic Medicine 1993;10(Suppl):38S. [MEDLINE: 567].
34. Ziegler 1991 {published data only} Ziegler D, Mayer P, Rathmann W, Gries FA. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Research and Clinical Practice 1991;14(1):63-73. [MEDLINE: 22].
35. Bertelsmann 1991 Bertelsmann FW, Faes ThJC, de Weerdt O, Yff GA, Heimans JJ, Lanting P. Treatment of diabetic autonomic neuropathy with the aldose reductase inhibitor statil. Diabetologia 1991;34(Suppl 2):A37. [MEDLINE: 12].
36. Bril 2006 Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29(1):68-72.
37. Canal 1984 Canal N, Comi G, Marchettini P, Pozza G. Effects of cyclandelate on diabetic peripheral neuropathy. British Journal of Clinical Practice. Supplement 1984;34:62-8. [MEDLINE: 17].
38. Fagius 1981 Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study. Journal of Neurology, Neurosurgery and Psychiatry 1981;44(11):991-1001. [MEDLINE: 34].
39. Gianni 1992 Gianni G, Vismara V, Borsini W, Castellani G, Marcacci G. Treatment of diabetic neuropathy by tolrestat. [Italian] [Trattamento con tolrestat nella neuropatia diabetica]. Rivista di Neurobiologia 1992;38(5):321-24. [MEDLINE: 41].
40. Gonen 1991 Gonen B, Bochenek W, Beg M, Graepel J, Tolrestat Study Group. The effect of withdrawal of tolrestat, an aldose reductase inhibitor, on signs, symptoms and nerve function in diabetic neuropathy. Diabetologia 1991;34:A153. [MEDLINE: 11].
41. Goto 1993 Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kito S, Matsuoka K, et al.A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabetic Medicine 1993; 10(SUPPL. 2):39S-43S. [MEDLINE: 46].
42. Greene 1989 Greene DA, Porte D, Bril V, Clements RS, Shamoon H, Ziedler A, Peterson MJ, Munster E, Pfeifer MA, Sorbinil Neuropathy Study Group. Clinical response to sorbinil treatment in diabetic neuropathy. Diabetologia 1989;32:493A. [MEDLINE: 48].
43. Guigliano 1991 Giugliano D, Marfella R, Salvatore T, Cozzolino D, Quatraro A, Bianchi C, Torella R. A double-blind controlled study on the effect of tolrestat on diabetic autonomic neuropathy. Diabetologia 1991;34:A152. [MEDLINE: 24].
44. Jaspan 1983 Jaspan J, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983;2(8353):758-62. [MEDLINE: 321].
45. Santiago 1993 Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, et al.Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. Journal of Diabetes and its Complications 1993;7(3):170-8. [MEDLINE: 517].
46. Sima 1993 Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, et al.Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. Journal of Diabetes and its Complications 1993;7(3):157-69. [MEDLINE: 521].
47. Terranova 1993 Terranova R, Luca S. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients]. [Italian]. Minerva Medica 1993;84(9):461-66. [MEDLINE: 563].
48. Young 1983 Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983;32(10):938-42. [MEDLINE: 570].
49. Nakajima 2005 Nakajima T, Fukui M, Deguchi M, Tanaka T, Tegoshi H, Hashimoto M, Tsubouchi Y, Hasegawa G, Nakamura N. Efficacy of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in a crossover trial. Journal of the Japan Diabetes Society 2005;48(8):601-6.
50. Abbott 1998 Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998;21(7):1071-5. [MEDLINE: 98317479].
51. Cameron 1997 Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(Suppl 2):S31-7. [MEDLINE: 97429858].
52. DCCTRG 1993 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329(14):977-86.
53. Dyck 1989 Dyck PJ. Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy?. Neurology 1989;39(1):111-8. [MEDLINE: 89082827].
54. Dyck 1997 Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49(1):229-39. [MEDLINE: 97365358].
55. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629-34.
56. Hamada 2004 Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treatments in Endocrinology 2004;3(4):245-255.
57. Leinninger 2006 Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nature Clinical Practice Neurology 2006;2(11):620-8.
58. Mayfield 1998 Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care 1998;21(12):2161-77. [MEDLINE: 99056490].
59. Nicolucci 1996 Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D, et al.A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration. Diabetic Medicine 1996;13(12):1017-26.
60. Oates 2002 Oates PJ. Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology 2002;50:325-92. [MEDLINE: 22187706].
61. Shaw 2003 Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of Diabetic Neuropathy. In: GriesFA, CameronNE, LowPA, ZieglerD editor(s). Textbook of Diabetic Neuropathy. New York: Thieme, 2003:64-82.
62. Ziegler 2006 Ziegler D. Treatment of diabetic polyneuropathy: Update 2006. Annals of the New York Academy of Sciences 2006;1084:250-66.
63. Airey 1997 Airey M, Bennett C, Nicolucci A, Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 1997, Issue 2.Art. No.: CD002182. DOI:10.1002/14651858.CD002182.